BioSpace News Archive

Haoma Medica announced a presentation made at the 2022 American Society for Bone and Mineral Research.

Agios Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on September 15, 2022, recommending the granting of a marketing authorization for PYRUKYND® for the treatment of pyruvate kinase deficiency in adult patients.

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the indication of Veklury® for the treatment of pediatric patients who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 and pediatric patients with SARS-CoV-2 with pneumonia who require supplemental oxygen.

Danicopan (ALXN2040) Add-On to ULTOMIRIS ® (ravulizumab-cwvz) or SOLIRIS ® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis.

NuGen Medical Devices Inc. is pleased to announce the appointment of Greg Gironda to the Company’s Advisory Board.

Merck Receives Positive CHMP Opinion for VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children.

Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced the approval from the National Medical Products Administration (NMPA) of China to initiate the Phase 3 clinical trial of LBS-008 in adolescent STGD1 in China.

EXUMA Biotech, Corp. announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 - 16, 2022.

Supira Medical, Inc. announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay.

Astria Therapeutics, Inc. today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th from 10:30am to 12:00pm ET.